ORIGINAL ARTICLESAddition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study
REFERENCES (38)
- et al.
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid
Lancet
(1994) - et al.
The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma
Respir Med
(2003) - et al.
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
J Allergy Clin Immunol
(2000) - et al.
Sustained bronchoprotection with montelukast but not formoterol as add-on therapy in asthmatics with the homozygous glycine-16 β2 adrenoceptor genotype
J Allergy Clin Immunol
(2002) - et al.
Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids
Chest
(2000) - et al.
Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids
Chest
(2001) - et al.
Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy
Chest
(2001) - et al.
Validation of a standardized version of the asthma quality of life questionnaire
Chest
(1999) - et al.
Determining a minimal important change in a disease-specific quality of life questionnaire
J Clin Epidemiol
(1994) - et al.
Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients
Lancet
(1995)
Deleterious effects of inhaled β-agonists: short-acting and long-acting agents differ
Chest
(2001)
Guidelines for the diagnosis and management of asthma: update on selected topics-2002 [Expert Panel Report]
Environ Int
(2002)
Systemic adverse effects of inhaled corticosteroid therapy
Arch Intern Med
(1999)
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
Am J Respir Crit Care Med
(1996)
Effect of inhaled formoterol and budesonide on exacerbations of asthma
N Engl J Med
(1997)
Effect of long-acting β2 agonists on exacerbation rates of asthma in children
Pediatr Pulmonol
(2003)
Montelukast: data from clinical trials in the management of asthma
Ann Pharmacother
(1999)
Montelukast (MK-0476), a leukotriene receptor antagonist provides additional clinical benefit to chronic asthmatic patients using inhaled beclomethasone
Eur Respir J
(1998)
Cited by (55)
Antileukotriene Therapy in Asthma
2014, Middleton's Allergy: Principles and Practice: Eighth EditionMontelukast in the treatment of mild to moderate persistent asthma
2011, Revue des Maladies RespiratoiresRole of add-on zileuton on total exhaled, large airway, and small airway/alveolar nitric oxide in moderate-severe persistent adult asthmatics on fluticasone 250 μg/Salmeterol 50 μg
2009, Pulmonary Pharmacology and TherapeuticsCitation Excerpt :However, clinical evidence to date strongly favors inhaled corticosteroids over cysteinyl leukotriene antagonists in the treatment of intermittent or mild persistent asthma with little benefit of combining the two [16,38,39]. In moderate to severe persistent asthma, there is greater clinical benefit, especially improved lung function, when combining ICS with a LABA compared to combining ICS with an anti-leukotriene agent [40–44]. In moderate to severe asthmatics already on ICS and LABA, the addition of montelukast or zileuton has not been well evaluated.
Patient-Centered Care for Childhood Asthma
2009, Journal for Nurse PractitionersMontelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis
2023, European Respiratory ReviewPersistent eosinophilic inflammation in adult asthmatics with high serum and urine levels of leukotriene e<inf>4</inf>
2021, Journal of Asthma and Allergy
This study was supported by Merck & Co Inc.
Copyright © 2004 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.